help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on February 2, 2006, doi:10.1164/rccm.200506-947OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200506-947OCv1
173/9/1016    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Inayama, M.
Right arrow Articles by Sone, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inayama, M.
Right arrow Articles by Sone, S.
American Journal of Respiratory and Critical Care Medicine Vol 173. pp. 1016-1022, (2006)
© 2006 American Thoracic Society
doi: 10.1164/rccm.200506-947OC

Original Article

A Novel I{kappa}B Kinase-beta Inhibitor Ameliorates Bleomycin-induced Pulmonary Fibrosis in Mice

Mami Inayama*, Yasuhiko Nishioka*, Momoyo Azuma, Susumu Muto, Yoshinori Aono, Hideki Makino, Kenji Tani, Hisanori Uehara, Keisuke Izumi, Akiko Itai and Saburo Sone

Departments of Internal Medicine and Molecular Therapeutics, and Molecular and Environmental Pathology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima; and Institute of Medicinal Molecular Design, Inc., Tokyo, Japan

Correspondence and requests for reprints should be addressed to Saburo Sone, M.D., Ph.D., Department of Internal Medicine and Molecular Therapeutics, Institute of Health Biosciences, the University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan. E-mail: ssone{at}clin.med.tokushima-u.ac.jp

Rationale: I{kappa}B kinase-beta is a critical regulator in the activation of nuclear factor-{kappa}B (NF-{kappa}B), a transcription factor related to the expression and regulation of proinflammatory cytokines.

Objective: To evaluate if inhibition of I{kappa}B kinase-beta ameliorates pneumonitis and pulmonary fibrosis.

Methods: We examined whether a novel I{kappa}B kinase-beta inhibitor, IMD-0354, attenuates bleomycin-induced pulmonary fibrosis in mice.

Measurements and Main Results: Administration of IMD-0354 significantly improved the loss of body weight and survival of mice treated with bleomycin, whereas IMD-0354 alone did not cause any morphologic change in the lung. When mice were evaluated 28 d after bleomycin administration, IMD-0354 dose-dependently reduced the collagen content and fibrotic scores as shown by histologic examination. The findings in the bronchoalveolar lavage demonstrated that the proportions of neutrophils and lymphocytes were decreased in mice treated with IMD-0354 on Day 7 and 14, respectively. IMD-0354 treatment was confirmed to inhibit the activation of NF-{kappa}B, but not activator protein-1, in the lungs treated with bleomycin. The production of inflammatory cytokines tumor necrosis factor-{alpha} and interleukin-1beta was reduced in the lungs of mice treated with IMD-0354.

Conclusions: These results suggest that IMD-0354 might be useful to ameliorate the inflammation in the lungs induced by fibrotic injury and the subsequent fibrogenesis via inhibiting the expression of profibrotic cytokines related to the activation of NF-{kappa}B.

Key Words: interleukin-1beta • nuclear factor-{kappa}B, tumor necrosis factor-{alpha}




This article has been cited by other articles:


Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. Fineschi, M. Bongiovanni, Y. Donati, S. Djaafar, F. Naso, L. Goffin, C. Barazzone Argiroffo, J.-C. Pache, J.-M. Dayer, S. Ferrari-Lacraz, et al.
In Vivo Investigations on Anti-Fibrotic Potential of Proteasome Inhibition in Lung and Skin Fibrosis
Am. J. Respir. Cell Mol. Biol., October 1, 2008; 39(4): 458 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Azuma, Y. Nishioka, Y. Aono, M. Inayama, H. Makino, J. Kishi, M. Shono, K. Kinoshita, H. Uehara, F. Ogushi, et al.
Role of {alpha}1-Acid Glycoprotein in Therapeutic Antifibrotic Effects of Imatinib with Macrolides in Mice
Am. J. Respir. Crit. Care Med., December 15, 2007; 176(12): 1243 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. Fujimoto, C. N. D'Alessandro-Gabazza, M. S. S. Palanki, P. E. Erdman, T. Takagi, E. C. Gabazza, N. E. Bruno, Y. Yano, T. Hayashi, S. Tamaki, et al.
Inhibition of Nuclear Factor-{kappa}B in T Cells Suppresses Lung Fibrosis
Am. J. Respir. Crit. Care Med., December 15, 2007; 176(12): 1251 - 1260.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. T. Stathopoulos, T. P. Sherrill, D.-S. Cheng, R. M. Scoggins, W. Han, V. V. Polosukhin, L. Connelly, F. E. Yull, B. Fingleton, and T. S. Blackwell
Epithelial NF-{kappa}B activation promotes urethane-induced lung carcinogenesis
PNAS, November 20, 2007; 104(47): 18514 - 18519.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. U. Wells and C. M. Hogaboam
Update in Diffuse Parenchymal Lung Disease 2006
Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 655 - 660.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. Avivi-Green, M. Singal, and W. F. Vogel
Discoidin Domain Receptor 1-deficient Mice Are Resistant to Bleomycin-induced Lung Fibrosis
Am. J. Respir. Crit. Care Med., August 15, 2006; 174(4): 420 - 427.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2006 American Thoracic Society 		  ATS State of the Art 2009